Notice2024-11591
Proposed Data Collection Submitted for Public Comment and Recommendations
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 28, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comments on a proposed information collection titled Needle Exchange Utilization Survey (NEXUS). This data collection is being created to develop a surveillance system to monitor drug use, prevention behaviors, and the infectious disease consequences of drug use in select urban and non-urban areas of the U.S.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 103 (Tuesday, May 28, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 103 (Tuesday, May 28, 2024)]
[Notices]
[Pages 46119-46120]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-11591]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-24FS; Docket No. CDC-2024-0038]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comments on a proposed information collection titled
Needle Exchange Utilization Survey (NEXUS). This data collection is
being created to develop a surveillance system to monitor drug use,
prevention behaviors, and the infectious disease consequences of drug
use in select urban and non-urban areas of the U.S.
DATES: CDC must receive written comments on or before July 29, 2024.
ADDRESSES: You may submit comments identified by Docket No. CDC-2024-
0038 by either of the following methods:
<bullet> Federal eRulemaking Portal: <a href="http://www.regulations.gov">www.regulations.gov</a>. Follow
the instructions for submitting comments.
<bullet> Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to <a href="http://www.regulations.gov">www.regulations.gov</a>.
Please note: Submit all comments through the Federal eRulemaking
portal (<a href="http://www.regulations.gov">www.regulations.gov</a>) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118;
Email: <a href="/cdn-cgi/l/email-protection#0d62606f4d6e696e236a627b"><span class="__cf_email__" data-cfemail="6807050a280b0c0b460f071e">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-
3520), Federal agencies must obtain approval from the Office of
Management and Budget (OMB) for each collection of information they
conduct or sponsor. In addition, the PRA also requires Federal agencies
to provide a 60-day notice in the Federal Register concerning each
proposed collection of information, including each new proposed
collection, each proposed extension of the existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of collecting information on those to
respond, including using appropriate automated, electronic, mechanical,
or other technological collection techniques or other forms of
information technology, e.g., permitting electronic responses; and
5. Assess information collection costs.
Proposed Project
Needle Exchange Utilization Survey (NEXUS)--New--National Center
for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of the Needle Exchange Utilization Survey (NEXUS) is to
develop a surveillance system to monitor drug use, prevention
behaviors, and the infectious disease consequences of drug use in 6-15
select urban and non-urban areas of the U.S. that the opioid crisis has
impacted. Such a surveillance system is needed to inform prevention
efforts and policy. The specific objectives of the project are to
assess the following among persons who inject drugs who are recruited
in syringe services programs (SSPs) and their peers who use drugs
through peer-driven recruitment: (1) drug use and sexual behaviors,
injection risk networks, receipt of prevention services, and barriers
to prevention and care; and (2) the prevalence of HIV and hepatitis C
(HCV) infections.
The project will involve a two-stage sampling approach. First, up
to 15 SSPs will be selected to ensure geographic diversity and
representation of key program characteristics, such as the syringe
distribution model (needs-based vs. all others) and length in operation
(<5 years, >=5 years). Second, SSP clients, the majority who are
persons who inject drugs (PWID), and their peers who use drugs will be
recruited through a combination of direct recruitment at each SSP and
peer-driven recruitment to partake in a survey and HCV and HIV testing.
Clients of SSPs and their peers who meet eligibility criteria will
complete a survey using an Electronic Data Capture system, a secure
web-based application for administering online surveys. The survey will
include questions on drug use and sexual behaviors, injection risk
networks, drug treatment history, history of drug use-related adverse
health outcomes, experiences with law enforcement, HIV and HCV testing
experience, and use of prevention and health care services. Lastly,
participants will be offered anonymous HIV and HCV testing in
conjunction with the survey, which they may refuse with no effect on
participation in the survey.
Data from NEXUS will be used to inform the planning and evaluation
of prevention programs at the local and national levels that aim to
reduce adverse health outcomes due to injection and non-injection drug
use and to contribute to the overall opioid crisis response efforts.
Data from NEXUS will also be used for an ongoing surveillance system in
the U.S. to monitor trends in drug use and the infectious disease
consequences of drug use.
Approximately 6,000 individuals will complete the eligibility
screener. Our target population is 300 participants per site or 4,500
for up to 15 sites. We anticipate that, on average, 25% or 1,499
persons (for up to 15 SSPs) will not be interested in completing a
questionnaire, yielding a maximum of
[[Page 46120]]
6,000 eligible participants. The total annualized burden is 3,126
hours. There are no other costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
No. of Average
No. of responses burden per Total
Respondent Form respondents per response burden (in
respondent (hours) hours)
----------------------------------------------------------------------------------------------------------------
Persons Screened.................... Eligibility Screening 5,400 1 5/60 450
Form English.
Persons Screened.................... Eligibility Screening 600 1 5/60 50
Form Spanish.
Persons who give permission......... Model Project Consent 4,050 1 5/60 338
Form English.
Persons who give permission......... Model Project 450 1 5/60 38
Permission Form
Spanish.
Eligible Participants............... NEXUS Survey English.. 4,050 1 30/60 2,025
Eligible Participants............... NEXUS Survey Spanish.. 450 1 30/60 225
---------------------------------------------------
Total........................... ...................... ........... ........... ........... 3,126
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2024-11591 Filed 5-24-24; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 28, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.